Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis

Journal of Neuro-Oncology

Volumn 97, Issue 2, 2010, Pages 171-185

  Koschny, Ronald ^a   Holland, Heidrun ^b   Sykora, Jaromir ^a,c   Erdal, Hande ^a   Krupp, Wolfgang ^b   Bauer, Manfred ^b   Bockmuehl, Ulrike ^d   Ahnert, Peter ^b   Meixensberger, Jürgen ^b   Stremmel, Wolfgang ^a   Walczak, Henning ^c,e   Ganten, Tom M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Department of Otorhinolaryngology Head and Neck   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Bortezomib; Esthesioneuroblastoma; Primary tumor cells; TRAIL

Indexed keywords

BORTEZOMIB; CASPASE 8; DEATH RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CASE REPORT; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ESTHESIONEUROBLASTOMA; HUMAN; HUMAN CELL; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL SEPARATION; CELLS, CULTURED; DRUG SYNERGISM; ESTHESIONEUROBLASTOMA, OLFACTORY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NOSE NEOPLASMS; PYRAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77950457766     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0010-6     Document Type: Article

References (35)

1. Diaz EM Jr, Johnigan RH 3rd, Pero C, El-Naggar AK, Roberts DB, Barker JL, DeMonte F (2005) Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 27:138-149
2. Bradley PJ, Jones NS, Robertson I (2003) Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 11:112-118
3. Zhang LW, Zhang MS, Qi J, Zhang JT, Li GL, Luo L, Wang ZC (2007) Management of intracranial invasive olfactory neuro-blastoma. Chin Med J (Engl) 120:224-227
4. Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T (2007) Olfactory neuroblastoma with spinal metastasis: case report. No Shinkei Geka 35:503-508
5. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM (1993) Esthesioneuroblastoma: prognosis and management. Neurosurgery 32:706-714 (discussion 714-715
6. Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, Gullane PJ, Perez-Ordonez B, Gilbert RW, Brown DH, Gentili F, O'Sullivan B, Irish JC (2008) Esthesioneuroblastoma: the Princess Margaret hospital experience. Head Neck 30:1607-1614
7. Dulguerov P, Allal AS, Calcaterra TC (2001) Esthesioneuro-blastoma: a meta-analysis and review. Lancet Oncol 2:683-690
8. Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, Moynihan TJ, Buckner JC (2008) Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol 90:201-204
9. Walczak H, Krammer PH (2000) The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58-66
10. MacFarlane M (2003) TRAIL-induced signalling and apoptosis. Toxicol Lett 139:89-97
11. Wu GS (2009) TRAIL as a target in anti-cancer therapy. Cancer Lett
12. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34-41
13. Koschny R, Walczak H, Ganten TM (2007) The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 85:923-935
14. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apop-tosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815
15. Pollack IF, Erff M, Ashkenazi A (2001) Direct stimulation of apoptotic signaling by soluble apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362-1369
16. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13:3403-3412
17. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP (2008) Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 7:135-145
18. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H (2007) TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45:649-658
19. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H (2005) Proteasome inhibition sensitizes hepato-cellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42:588-597
20. Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Kirsten H, Ahnert P (2007) Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet 173:89-96
21. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12:2640-2646
22. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apop-tosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1): S86-S96
23. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599-609
24. Strieder V, Lutz W (2002) Regulation of N-myc expression in development and disease. Cancer Lett 180:107-119
25. Castaneda VL, Cheah MS, Saldivar VA, Richmond CM, Parmley RT (1991) Cytogenetic and molecular evaluation of clinically aggressive esthesioneuroblastoma. Am J Pediatr Hematol Oncol 13:62-70
26. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C (2002) Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277:25020-25025
27. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118:1979-1990
28. Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ (2003) Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 63: 1122-1129
29. Ashley DM, Riffkin CD, Muscat AM, Knight MJ, Kaye AH, Novak U, Hawkins CJ (2005) Caspase 8 is absent or low in many ex vivo gliomas. Cancer 104:1487-1496
30. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocar-cinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129-G136
31. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff H, Wajant H (2006) TRAIL promotes metastasis of human pancreatic ductal adeno-carcinoma. Oncogene 25:7434-7439
32. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22:4953-4963
33. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H, Walczak H, Leverkus M (2008) Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL-and CD95L-mediated apop-tosis. Oncogene 27:3211-3220
34. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61:1162-1170
35. Kim JW, Kong IG, Lee CH, Kim DY, Rhee CS, Min YG, Kim CW, Chung JH (2008) Expression of Bcl-2 in olfactory neuro-blastoma and its association with chemotherapy and survival. Otolaryngol Head Neck Surg 139:708-712